Lloyds Enterprises Ltd
LLOYDSENTLloyds Enterprises Ltd's earnings have outrun its stock. EPS grew +413.5% in a year against a +8.8% price move.
The sharpest disagreement: profits are rising, but only −33% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (12 weeks in) while the P/E sits at the 100th percentile of its own 8-year range. Underneath, the last four quarters read improving — profit +176.0% year on year, and −33% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Lloyds Enterprises Ltd trades at ₹83.4, in a confirmed uptrend and 12 weeks into that stage. That is +25.4% against its own 200-day average. It sits at 100% of a 52-week range of ₹43 to ₹83. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 22 straight weeks.
Today the stock is in a confirmed uptrend — week 12 of stage 2, confirmed. At ₹83.4 it trades +25.4% versus its 200-day average and sits at 100% of its 52-week range (₹43–₹83).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +2,155% while the NIFTY 500 moved +280% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 22 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Lloyds Enterprises Ltd's story is not scored yet against the markers our research file set on 17 May 2026. Where it sits in its own cycle: CYCLE_BOTTOM. Still open: Promoter holding dropped 11.19pp from 73.91% to 62.72% in Sep 2025 with no exchange announcement explaining the cause.
Our read, 17 May 2026. PAT tripled in FY26 on Steel segment result expanding 8.6x; PE at 22nd percentile while earnings accelerate — classic compression-then-rerating setup.
What is proven. PAT tripled in FY26 on Steel segment result expanding 8.6x; PE at 22nd percentile while earnings accelerate — classic compression-then-rerating setup.
What is not proven yet. Promoter holding dropped 11.19pp from 73.91% to 62.72% in Sep 2025 with no exchange announcement explaining the cause.
The test written in advance. Promoter Stake Reduction — Undisclosed Rationale — Promoter Stake Reduction — Undisclosed Rationale Any further decline below 62% in shareholding filings by the next result.
The test written in advance. Concurrent Corporate Actions Execution Risk — Concurrent Corporate Actions Execution Risk by the next result.
The test written in advance. Steel Segment Margin Sustainability — Steel Segment Margin Sustainability Q1 FY27 Steel segment result vs ₹74 Cr run-rate (₹297.93 Cr / 4 quarters) by the next result.
| Dial | Now | Was | Why it matters | Watch line |
|---|---|---|---|---|
| Steel Segment Operating Leverage | HIGH | — | Steel segment result surged from ₹34.58 Cr (FY25) to ₹297.93 Cr (FY26) — 8.6x expansion on 22% revenue growth. | Any further decline below 62% in shareholding filings |
| Geomysore Gold Mine Commercialization | MEDIUM | — | 31.58% stake in India's first privately operated gold mine (post-independence); ₹950 Cr/year peak revenue disclosed; commercial… | Any further decline below 62% in shareholding filings |
Lever 1 · Operating leverage — BUILDING. Steel segment result surged from ₹34.58 Cr (FY25) to ₹297.93 Cr (FY26) — 8.6x expansion on 22% revenue growth. What proves it keeps working: Steel Segment Operating Leverage. It stops working if Any further decline below 62% in shareholding filings.
Sources: our stock research file (17 May 2026) · quarterly results through Mar 26. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Lloyds Enterprises Ltd reported ₹720 Cr of revenue in the Mar 26 quarter, +47.2% year on year. That is the 5th straight quarter of year-on-year growth. Over 10 years it has compounded at 29.5% a year. The last full year, FY26, came in at ₹1,756 Cr. The last four reported quarters add to ₹1,757 Cr.
FY26 revenue came in at ₹1,756 Cr (+18.0% on the year), capping 10 years at 29.5% compound. The latest quarter (Mar 26) printed ₹720 Cr, +47.2% year on year — the 5th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +14.6% growth against the decade's 29.5% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +18.2% over the last 4 quarters against +35.4%/yr over the last 8 — rolling over; TTM profit +239.8% vs +54.6%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Lloyds Enterprises Ltd's operating margin is 6.0% in the Mar 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −311.0% to 13.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 6.0%, +1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −311.0%–13.0%.
Why the margin moved: operating margin went +1.2 pp year on year while gross margin went +5.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Lloyds Enterprises Ltd earned ₹69.0 Cr of net profit in the Mar 26 quarter, +176.0% year on year. Full-year FY26 profit was ₹417 Cr. That is 9.6% of the quarter's revenue. The same quarter a year earlier earned ₹25.0 Cr.
Mar 26 profit was ₹69.0 Cr, +176.0% year on year. On the full year, FY26 printed ₹417 Cr (+239.0%).
Why profit moved: revenue contributed +47.2% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +397.1% vs revenue +14.6%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years −33% of Lloyds Enterprises Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−361 Cr of operating cash against ₹417 Cr of profit. After ₹222 Cr of capital spending, ₹−583 Cr was left as free cash.
FY26: operating cash of ₹−361 Cr against reported profit of ₹417 Cr, leaving free cash of ₹−583 Cr after ₹222 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −33% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at −33%: the cash cycle stretched 170 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 170 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Lloyds Enterprises Ltd's cash conversion cycle runs 170 days in FY26, up from 0 days in FY21. Capital spending ran ₹496 Cr over the last 3 years. At FY26 sales of ₹1,756 Cr each day of that cycle holds about ₹4.8 Cr, so roughly ₹818 Cr sits inside the business at any moment.
FY26: debtors at 56 days, inventory at 188 days — roughly 6.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 170 days, looser than FY21's 0.
The full loop: cash goes out to suppliers and production on day 0; stock waits 188 days to sell; customers pay about 56 days after that; and suppliers themselves are paid at 74 days — netting out to the 170-day cycle.
In money terms: at FY26 sales of ₹1,756 Cr, each day of the cycle holds about ₹4.8 Cr — so the 170-day loop keeps roughly ₹818 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹496 Cr over the last 3 fiscal years against ₹39.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹71.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Lloyds Enterprises Ltd earns a ROCE of 4% in FY26. That is up from a trough of −1% in FY16. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 23.7% net margin on 0.24× asset turns.
FY26 ROCE is 4%, recovered from a FY16 trough of −1% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 23.7% net margin × 0.24× asset turns × 1.73× balance-sheet leverage ≈ 9.8% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 119% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Lloyds Enterprises Ltd carries ₹798 Cr of borrowings against ₹4,143 Cr of equity in FY26, a debt-to-equity of 0.19. Operating profit covers the interest bill 2×. Over 5 years borrowings went from ₹2.0 Cr to ₹798 Cr. Capital spending ran ₹496 Cr across the last 3 of those years.
Why this happened. The Steel segment generated ₹765.82 Cr in FY26 revenue vs ₹626.76 Cr in FY25 (+22%), yet segment result expanded 8.6x to ₹297.93 Cr. This implies non-linear margin recovery — likely driven by commodity price tailwinds and fixed-cost absorption as volumes scaled. Q4 FY26 showed consolidated EBITDA margin at 6.3% vs 5.1% in Q4 FY25 (+120 bps). Sustainability depends on steel price trajectory; reversal to FY24 segment result levels (₹34 Cr) is the primary downside.
FY26: borrowings of ₹798 Cr against equity of ₹4,143 Cr — a debt-to-equity of 0.19. Operating profit covers the interest bill 2×. Over 5 years borrowings went from ₹2.0 Cr to ₹798 Cr while capital spending ran ₹496 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 119% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 11.2 points of Lloyds Enterprises Ltd over 8 quarters, the biggest move on the register. That takes promoters to 62.7% of the company. Foreign institutions moved +0.4 points over the same window, to 0.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
Why this happened. 31.58% stake in India's first privately operated gold mine (post-independence); ₹950 Cr/year peak revenue disclosed; commercial production imminent.
The register over the last two years — Promoters: −11.2 points over 8 quarters to 62.7%; Foreign institutions: +0.4 points over 8 quarters to 0.7%; Domestic institutions: +0.1 points over 8 quarters to 0.1%.
🚨 Why the register moved: promoters drove it (−11.2 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Lloyds Enterprises Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Lloyds Enterprises Ltd trades at 1,155.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 73.5×, measured across 8.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 1,155.0× is about the priciest it has ever traded, against a long-run median of 73.5× measured over 8.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +413.5% against a +8.8% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +59.1%/yr price move, ~+47.6%/yr came from earnings growth and ~+11.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources disagree by up to 119% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Lloyds Enterprises Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −45.3% at the trough to +176.0% off a 4-quarter-old trough (single-quarter readings), ROCE slipping at 4.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +18.0% | +66.6% | +345.6% | +29.5% |
| Profit | +239.0% | +83.0% | +234.2% | — |
| EPS | +413.5% | +81.1% | +185.6% | — |
| Share price | +8.8% | +34.4% | +59.1% | +42.4% |
4-Factor Sector Score
57.1/100 — rank 8 of 49 in Trading · 71% evidence confidence
Lloyds Enterprises Ltd scores 57.1 out of 100 against the 49 companies it is compared with in Trading, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 21.2 + 9.7 + 8.6 + 17.6 = 57.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Rashi Peripherals LtdRPTECH | 69.2/100Favorable setup75% evidence | LEADER | 23.5/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 15.1/25 ROCE 16.8% · OPM 3% 76% evidence | 10.8/20 P/E 18.6× · PEG — 15% evidence | 19.8/20 RS sector 80.3% · RS bench 99% · 1Y 209.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 23.5 + 15.1 + 10.8 + 19.8 = 69.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Magnus Steel & Infra Ltd517320 | 66.8/100Thin evidence · provisional56% evidence | 27.0/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.6/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 46.1% · 1Y 1449.6%5 of 6 weeks ahead to 2026-06-28 25% evidence | |
| Exact sum: 27 + 18.6 + 9.2 + 12 = 66.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Shankara Buildpro LtdBUILDPRO | 62.2/100Mixed-positive evidence63% evidence | BREAKING OUT | 24.1/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.6/25 ROCE 39% · OPM 3.2% 100% evidence | 10.5/20 P/E 24.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 24.1 + 17.6 + 10.5 + 10 = 62.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Mangalam Global Enterprise LtdMGEL | 61.8/100Mixed-positive evidence65% evidence | ASLEEP | 24.4/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 16.5/25 ROCE 17% · OPM 1.9% 95% evidence | 11.2/20 P/E 13× · PEG — 15% evidence | 9.7/20 RS sector — · RS bench -0.2% · 1Y —3 of 4 weeks ahead 25% evidence |
| Exact sum: 24.4 + 16.5 + 11.2 + 9.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Ivalue Infosolutions LtdIVALUE | 60.6/100Mixed-positive evidence60% evidence | TURNING | 20.6/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 19.0/25 ROCE 25.4% · OPM 10% 95% evidence | 11.0/20 P/E 14× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 10 weeks ahead 0% evidence |
| Exact sum: 20.6 + 19 + 11 + 10 = 60.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Vision Infra Equipment Solutions LtdVIESL | 60.2/100Thin evidence · provisional51% evidence | FADING | 18.8/35 Revenue — · PAT — · OPM change 2 pp 13% evidence | 19.1/25 ROCE 19.6% · OPM 27% 95% evidence | 10.5/20 P/E 24.8× · PEG — 15% evidence | 11.8/20 RS sector 4.4% · RS bench 17% · 1Y 88.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 19.1 + 10.5 + 11.8 = 60.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Euro Pratik Sales LtdEUROPRATIK | 58.7/100Mixed-positive evidence69% evidence | TURNING | 14.3/35 Revenue 18% · PAT 4% · OPM change 1 pp 88% evidence | 19.6/25 ROCE 38.4% · OPM 27% 100% evidence | 14.8/20 P/E 38.7× · PEG 0.62 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —7 of 10 weeks ahead 0% evidence |
| Exact sum: 14.3 + 19.6 + 14.8 + 10 = 58.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 8Lloyds Enterprises Ltdthis pageLLOYDSENT | 57.1/100Mixed-positive evidence71% evidence | LEADER | 21.2/35 Revenue 18.2% · PAT 100% · OPM change 1 pp 83% evidence | 9.7/25 ROCE 3.7% · OPM 6% 76% evidence | 8.6/20 P/E 1155× · PEG — 15% evidence | 17.6/20 RS sector 10.5% · RS bench 25.5% · 1Y 12.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 9.7 + 8.6 + 17.6 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Arisinfra Solutions LtdARIS | 56.6/100Mixed-positive evidence65% evidence | ASLEEP | 20.6/35 Revenue 39.1% · PAT 100% · OPM change 2 pp 95% evidence | 15.7/25 ROCE 15.6% · OPM 11% 95% evidence | 10.8/20 P/E 16.4× · PEG — 15% evidence | 9.5/20 RS sector — · RS bench -0.4% · 1Y -11.3%3 of 10 weeks ahead 25% evidence |
| Exact sum: 20.6 + 15.7 + 10.8 + 9.5 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Tembo Global Industries LtdTEMBO | 56.5/100Mixed-positive evidence70% evidence | ASLEEP | 19.8/35 Revenue 48.5% · PAT 78.2% · OPM change 1 pp 83% evidence | 18.1/25 ROCE 22.8% · OPM 11% 95% evidence | 11.3/20 P/E 12.4× · PEG — 15% evidence | 7.3/20 RS sector -24.5% · RS bench -0.3% · 1Y -87.8%3 of 10 weeks ahead 70% evidence |
| Exact sum: 19.8 + 18.1 + 11.3 + 7.3 = 56.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Sudarshan Pharma Industries Ltd543828 | 55.7/100Mixed-positive evidence78% evidence | LEADER | 18.6/35 Revenue 38.9% · PAT 53.3% · OPM change -1 pp 83% evidence | 14.1/25 ROCE 15.1% · OPM 9% 76% evidence | 9.2/20 P/E 35.1× · PEG — 50% evidence | 13.8/20 RS sector 0.1% · RS bench 13% · 1Y 20.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 14.1 + 9.2 + 13.8 = 55.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Aayush Art and Bullion Ltd540718 | 54.8/100Thin evidence · provisional54% evidence | ASLEEP | 20.9/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.7/25 ROCE 18.9% · OPM 6% 76% evidence | 8.9/20 P/E 239× · PEG — 15% evidence | 11.3/20 RS sector -3.3% · RS bench 9.4% · 1Y 32.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 13.7 + 8.9 + 11.3 = 54.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Nupur Recyclers LtdNRL | 53.6/100Mixed-positive evidence68% evidence | TURNING | 15.7/35 Revenue 36.4% · PAT 1.2% · OPM change 1.1 pp 83% evidence | 16.1/25 ROCE 15.1% · OPM 6.4% 95% evidence | 9.6/20 P/E 56.8× · PEG — 50% evidence | 12.2/20 RS sector — · RS bench 71.6% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 15.7 + 16.1 + 9.6 + 12.2 = 53.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Yogi Ltd511702 | 52.5/100Mixed-positive evidence61% evidence | ASLEEP | 24.2/35 Revenue 100% · PAT 100% · OPM change 3.6 pp 53% evidence | 11.2/25 ROCE 12.8% · OPM 4.4% 76% evidence | 9.9/20 P/E 35.2× · PEG — 15% evidence | 7.2/20 RS sector -18% · RS bench -6.5% · 1Y -10.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 24.2 + 11.2 + 9.9 + 7.2 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Bizotic Commercial Ltd543926 | 51.3/100Thin evidence · provisional58% evidence | ASLEEP | 19.7/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.1/25 ROCE 26.8% · OPM 8% 76% evidence | 10.3/20 P/E 28.8× · PEG — 50% evidence | 2.2/20 RS sector -38.9% · RS bench -31% · 1Y 88%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 19.1 + 10.3 + 2.2 = 51.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Patel Retail LtdPATELRMART | 51.3/100Thin evidence · provisional56% evidence | ASLEEP | 16.0/35 Revenue 27.7% · PAT 54.4% · OPM change -1.9 pp 83% evidence | 14.6/25 ROCE 15.3% · OPM 5.2% 95% evidence | 10.7/20 P/E 18.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -15.9%6 of 10 weeks ahead 0% evidence |
| Exact sum: 16 + 14.6 + 10.7 + 10 = 51.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Fabtech Technologies LtdFABTECH | 51.2/100Thin evidence · provisional52% evidence | ASLEEP | 17.4/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.7/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.1/20 P/E 13.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 17.4 + 12.7 + 11.1 + 10 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Onix Solar Energy Ltd513119 | 50.5/100Mixed-positive evidence75% evidence | ASLEEP | 22.1/35 Revenue 100% · PAT 100% · OPM change 23 pp 95% evidence | 11.2/25 ROCE 10% · OPM 30% 76% evidence | 10.4/20 P/E 28.4× · PEG — 15% evidence | 6.8/20 RS sector -17.8% · RS bench 11.5% · 1Y 4.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 11.2 + 10.4 + 6.8 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19SG Mart LtdSGMART | 50.4/100Mixed-positive evidence90% evidence | LEADER | 14.4/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 95% evidence | 9.3/25 ROCE 10.2% · OPM 4.5% 95% evidence | 8.3/20 P/E 72.6× · PEG 1.92 65% evidence | 18.4/20 RS sector 36.6% · RS bench 52% · 1Y 120.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.4 + 9.3 + 8.3 + 18.4 = 50.4 · Decision use: Price leads the evidence: RS versus the benchmark is 52%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20PTC India LtdPTC | 48.6/100Mixed-negative evidence82% evidence | ASLEEP | 13.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.9/25 ROCE 13.4% · OPM 3.1% 76% evidence | 10.6/20 P/E 11.8× · PEG — 50% evidence | 11.9/20 RS sector 0.3% · RS bench 13.9% · 1Y 12.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 12.9 + 10.6 + 11.9 = 48.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Adani Enterprises LtdADANIENT | 47.8/100Mixed-negative evidence93% evidence | LEADER | 14.4/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.8/25 ROCE 5.8% · OPM 15% 100% evidence | 7.7/20 P/E 172× · PEG 1.96 65% evidence | 16.9/20 RS sector 7.7% · RS bench 21.5% · 1Y 32.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.4 + 8.8 + 7.7 + 16.9 = 47.8 · Decision use: Price leads the evidence: RS versus the benchmark is 21.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22Shiv Aum Steels LtdSHIVAUM | 47.4/100Thin evidence · provisional50% evidence | TURNING | 16.7/35 Revenue — · PAT — · OPM change 0.5 pp 32% evidence | 11.4/25 ROCE 8% · OPM 3.8% 95% evidence | 7.8/20 P/E 79.5× · PEG — 50% evidence | 11.5/20 RS sector — · RS bench 26.8% · 1Y —1 of 1 week ahead 25% evidence |
| Exact sum: 16.7 + 11.4 + 7.8 + 11.5 = 47.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Hardwyn India LtdHARDWYN | 46.1/100Mixed-negative evidence83% evidence | ASLEEP | 20.3/35 Revenue 8.3% · PAT 17.5% · OPM change 3.5 pp 83% evidence | 12.3/25 ROCE 4.8% · OPM 10% 95% evidence | 11.7/20 P/E 58.3× · PEG — 50% evidence | 1.8/20 RS sector -43.9% · RS bench -16.4% · 1Y -19%3 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 12.3 + 11.7 + 1.8 = 46.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24BN Agrochem LtdBNAGROCHEM | 44.4/100Mixed-negative evidence73% evidence | ASLEEP | 24.3/35 Revenue 100% · PAT 57.3% · OPM change 20.5 pp 88% evidence | 4.4/25 ROCE 4.4% · OPM 1.6% 100% evidence | 9.4/20 P/E 75.4× · PEG — 15% evidence | 6.3/20 RS sector -18.8% · RS bench -16.6% · 1Y -14.2%7 of 8 weeks ahead 70% evidence |
| Exact sum: 24.3 + 4.4 + 9.4 + 6.3 = 44.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.8% and the one-year return is -14.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 25State Trading Corporation of India LtdSTCINDIA | 44.0/100Thin evidence · provisional54% evidence | ASLEEP | 18.6/35 Revenue — · PAT 100% · OPM change -14.6 pp 43% evidence | 7.5/25 ROCE -0.9% · OPM — 60% evidence | 12.1/20 P/E 16× · PEG — 50% evidence | 5.8/20 RS sector -30.4% · RS bench -4.4% · 1Y -4.7%5 of 11 weeks ahead 70% evidence |
| Exact sum: 18.6 + 7.5 + 12.1 + 5.8 = 44 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26MMTC LtdMMTC | 43.7/100Mixed-negative evidence86% evidence | ASLEEP | 14.9/35 Revenue 0% · PAT 100% · OPM change -5633.5 pp 88% evidence | 8.1/25 ROCE 8.7% · OPM — 84% evidence | 13.8/20 P/E 95.9× · PEG 0.92 100% evidence | 6.9/20 RS sector -22.5% · RS bench -2.3% · 1Y -3.5%7 of 11 weeks ahead 70% evidence |
| Exact sum: 14.9 + 8.1 + 13.8 + 6.9 = 43.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 27RRP Semiconductor LtdRRP | 42.7/100Thin evidence · provisional51% evidence | 12.2/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 62% evidence | 5.5/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.0/20 RS sector 62.6% · RS bench 6.5% · 1Y 167.9%0 of 1 week ahead 70% evidence | |
| Exact sum: 12.2 + 5.5 + 10 + 15 = 42.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Riddhi Siddhi Gluco Biols Ltd524480 | 42.6/100Mixed-negative evidence78% evidence | FADING | 12.0/35 Revenue 74.8% · PAT 0% · OPM change -77 pp 83% evidence | 6.3/25 ROCE 2.7% · OPM -89% 76% evidence | 6.9/20 P/E 28.5× · PEG — 50% evidence | 17.4/20 RS sector 19.4% · RS bench 34.3% · 1Y 42.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 6.3 + 6.9 + 17.4 = 42.6 · Decision use: Price leads the evidence: RS versus the benchmark is 34.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 29Cropster Agro Ltd523105 | 40.8/100Mixed-negative evidence65% evidence | 16.0/35 Revenue 28.4% · PAT 6.5% · OPM change 2.1 pp 83% evidence | 11.6/25 ROCE 12.4% · OPM 8.7% 76% evidence | 10.2/20 P/E 31× · PEG — 15% evidence | 3.0/20 RS sector -73.4% · RS bench -62.7% · 1Y -69.5%0 of 4 weeks ahead 70% evidence | |
| Exact sum: 16 + 11.6 + 10.2 + 3 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Neueon Corporation LtdNEUEON | 40.7/100Thin evidence · provisional59% evidence | ASLEEP | 11.6/35 Revenue 100% · PAT -80% · OPM change -1039 pp 71% evidence | 3.8/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.3/20 RS sector 16.9% · RS bench 28.6% · 1Y —6 of 12 weeks ahead 70% evidence |
| Exact sum: 11.6 + 3.8 + 10 + 15.3 = 40.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 31Hexa Tradex LtdHEXATRADEX | 39.9/100Mixed-negative evidence65% evidence | ASLEEP | 16.7/35 Revenue 0.4% · PAT 65% · OPM change 13.6 pp 62% evidence | 4.3/25 ROCE -0.1% · OPM -191.7% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.9/20 RS sector -15.9% · RS bench -3.9% · 1Y -9.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 4.3 + 10 + 8.9 = 39.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Kothari Industrial Corporation LtdKOTIC | 35.1/100Thin evidence · provisional59% evidence | ASLEEP | 19.8/35 Revenue 100% · PAT -80% · OPM change -1 pp 62% evidence | 1.8/25 ROCE -28.9% · OPM -54% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -59.8% · RS bench -47.3% · 1Y -65.6%0 of 7 weeks ahead 70% evidence |
| Exact sum: 19.8 + 1.8 + 10 + 3.5 = 35.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Shanti Overseas (India) LtdSHANTI | 32.5/100Thin evidence · provisional56% evidence | 11.3/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.6/25 ROCE -25.2% · OPM -216.5% 71% evidence | 13.3/20 P/E 3× · PEG — 50% evidence | 3.3/20 RS sector -61.4% · RS bench -49.7% · 1Y -56.4%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.3 + 4.6 + 13.3 + 3.3 = 32.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Dhunseri Ventures LtdDVL | 31.0/100Adverse evidence69% evidence | ASLEEP | 11.7/35 Revenue -30.8% · PAT -38.9% · OPM change -4 pp 62% evidence | 6.0/25 ROCE 6.7% · OPM -85% 95% evidence | 8.6/20 P/E 6× · PEG — 50% evidence | 4.7/20 RS sector -45.6% · RS bench -4.9% · 1Y -23%2 of 10 weeks ahead 70% evidence |
| Exact sum: 11.7 + 6 + 8.6 + 4.7 = 31 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Uniphos Enterprises LtdUNIENTER | 28.6/100Adverse evidence69% evidence | ASLEEP | 12.9/35 Revenue -71.3% · PAT 100% · OPM change -0.9 pp 62% evidence | 3.1/25 ROCE 0.8% · OPM -3.1% 95% evidence | 8.1/20 P/E 32.6× · PEG — 50% evidence | 4.5/20 RS sector -45% · RS bench -23.7% · 1Y -37.7%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.9 + 3.1 + 8.1 + 4.5 = 28.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Oswal Agro Mills LtdOSWALAGRO | 24.4/100Adverse evidence67% evidence | ASLEEP | 2.8/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.7/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.9/20 RS sector -51.6% · RS bench -29.1% · 1Y -48.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 2.8 + 7.7 + 10 + 3.9 = 24.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Proventus Agrocom LtdPROV | 57.4/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.9/25 ROCE 11.5% · OPM 1.8% 95% evidence | 13.1/20 P/E 42× · PEG — 50% evidence | 11.8/20 RS sector — · RS bench 30.3% · 1Y —7 of 7 weeks ahead 25% evidence |
| Exact sum: 19.6 + 12.9 + 13.1 + 11.8 = 57.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38Mardia Samyoung Capillary Tubes Company LtdMSCTC | 57.2/100Thin evidence · provisional32% evidence | 20.6/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.6/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.7/20 P/E 687× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 74.6% · 1Y 204.6%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.6 + 15.6 + 8.7 + 12.3 = 57.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 39SK Minerals & Additives Ltd544584 | 55.6/100Thin evidence · provisional31% evidence | 16.2/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.3/25 ROCE 26.2% · OPM 10% 76% evidence | 10.1/20 P/E 31.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.2 + 19.3 + 10.1 + 10 = 55.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 40Monika Alcobev LtdMONIKA | 54.3/100Thin evidence · provisional22% evidence | 16.3/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.4/25 ROCE 21% · OPM 15% 57% evidence | 10.6/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -21.6%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.3 + 17.4 + 10.6 + 10 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 41Pramara Promotions LtdPRAMARA | 53.3/100Thin evidence · provisional47% evidence | 16.6/35 Revenue — · PAT — · OPM change -1 pp 15% evidence | 14.4/25 ROCE 15.2% · OPM 15% 71% evidence | 7.3/20 P/E 51.3× · PEG — 50% evidence | 15.0/20 RS sector 8% · RS bench 29% · 1Y 63.1%10 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 16.6 + 14.4 + 7.3 + 15 = 53.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42BMW Ventures LtdBMW | 52.2/100Thin evidence · provisional26% evidence | 17.9/35 Revenue — · PAT — · OPM change 0 pp 24% evidence | 13.2/25 ROCE 13.6% · OPM 4% 57% evidence | 11.1/20 P/E 13.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 17.9 + 13.2 + 11.1 + 10 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Manbro Industries Ltd512595 | 51.7/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.4/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector -18.9% · RS bench 37.2% · 1Y 36.1%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.4 + 10 + 10 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44Shah Foods Ltd519031 | 50.9/100Thin evidence · provisional17% evidence | 17.3/35 Revenue — · PAT — · OPM change -10.7 pp 3% evidence | 12.3/25 ROCE — · OPM -3.3% 30% evidence | 8.9/20 P/E 265× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 112.7% · 1Y — 25% evidence | |
| Exact sum: 17.3 + 12.3 + 8.9 + 12.4 = 50.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Le Merite Exports LtdLEMERITE | 48.6/100Thin evidence · provisional46% evidence | 18.9/35 Revenue — · PAT — · OPM change 0.9 pp 15% evidence | 9.3/25 ROCE 8.6% · OPM 2.8% 71% evidence | 9.2/20 P/E 87× · PEG — 15% evidence | 11.2/20 RS sector -9.9% · RS bench 15% · 1Y 46.8%2 of 12 weeks ahead to 2026-05-17 100% evidence | |
| Exact sum: 18.9 + 9.3 + 9.2 + 11.2 = 48.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46Keto Motors Ltd537392 | 46.7/100Thin evidence · provisional21% evidence | 16.9/35 Revenue — · PAT -41.7% · OPM change — 12% evidence | 7.3/25 ROCE -2.2% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.5/20 RS sector — · RS bench 315% · 1Y — 25% evidence | |
| Exact sum: 16.9 + 7.3 + 10 + 12.5 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Satani Bearings Ltd505703 | 44.8/100Thin evidence · provisional37% evidence | ASLEEP | 20.1/35 Revenue — · PAT 100% · OPM change — 29% evidence | 4.8/25 ROCE 1% · OPM 1.5% 76% evidence | 8.5/20 P/E 11096× · PEG — 15% evidence | 11.4/20 RS sector — · RS bench 25.9% · 1Y 168.4%0 of 10 weeks ahead 25% evidence |
| Exact sum: 20.1 + 4.8 + 8.5 + 11.4 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48A-1 LtdA1L | 41.6/100Thin evidence · provisional50% evidence | 16.1/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 11.0/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.8/20 P/E 383× · PEG — 15% evidence | 5.7/20 RS sector -26.2% · RS bench -16% · 1Y 21.6%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.1 + 11 + 8.8 + 5.7 = 41.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49Blue Pearl Agriventures LtdBPAGRI | 38.5/100Thin evidence · provisional50% evidence | 17.2/35 Revenue 100% · PAT -46.7% · OPM change -2.5 pp 53% evidence | 7.7/25 ROCE 2.6% · OPM 2.8% 57% evidence | 8.6/20 P/E 5705× · PEG — 15% evidence | 5.0/20 RS sector -35.2% · RS bench -25.1% · 1Y -43.4%1 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 17.2 + 7.7 + 8.6 + 5 = 38.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Lloyds Enterprises Ltd's share price today?
Lloyds Enterprises Ltd trades at ₹83.4, +8.8% over the past year. The company is valued at ₹12,726 Cr. The stock sits at the very top of its 52-week range (₹43–₹83), +25.4% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 12 weeks in. — as of 7 August 2026.
What were Lloyds Enterprises Ltd's latest quarterly results?
Lloyds Enterprises Ltd reported revenue of ₹720 Cr and net profit of ₹69.0 Cr for the Mar 26 quarter. Revenue rose 47.2% and profit rose 176.0% year on year. Earnings per share were ₹0.26. The operating margin was 6.0%, 1.0 pp higher than a year earlier. — as of 7 August 2026.
What is Lloyds Enterprises Ltd's revenue?
Lloyds Enterprises Ltd reported revenue of ₹720 Cr in the Mar 26 quarter, +47.2% year on year. For the full FY26 fiscal year, revenue was ₹1,756 Cr (+18.0%). Over the last 10 years revenue compounded at 29.5% a year. — as of 7 August 2026.
What is Lloyds Enterprises Ltd's profit?
Lloyds Enterprises Ltd earned ₹69.0 Cr of net profit in the Mar 26 quarter, +176.0% year on year. Full-year FY26 profit was ₹417 Cr. The operating margin ran 6.0% in the latest quarter. — as of 7 August 2026.
What is Lloyds Enterprises Ltd's market cap?
Lloyds Enterprises Ltd's market capitalisation is ₹12,726 Cr at a share price of ₹83.4. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 7 August 2026.
What is Lloyds Enterprises Ltd's P/E ratio?
Lloyds Enterprises Ltd trades at a P/E of 1,155.0×, at the most expensive it has been in 8 years, against a long-run median of 73.5×. This is a comparison with the stock's own history, not a value call — as of 7 August 2026.
Does Lloyds Enterprises Ltd pay a dividend?
Yes — Lloyds Enterprises Ltd's dividend payout was 8% of profit in FY26, and it recorded a payout in 5 of its last 14 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 7 August 2026.
Is Lloyds Enterprises Ltd overvalued?
On its own history, Lloyds Enterprises Ltd looks expensive: its P/E of 1,155.0× sits at the most expensive it has been in 8 years (long-run median 73.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 7 August 2026.
Is Lloyds Enterprises Ltd growing?
Yes — Lloyds Enterprises Ltd is growing: latest-quarter revenue +47.2% year on year, profit +176.0%, and the margin +1.0 pp at 6.0%. The earnings engine currently reads: improving — as of 7 August 2026.
How is Lloyds Enterprises Ltd performing?
Lloyds Enterprises Ltd is in a confirmed uptrend, 12 weeks in. Its latest quarter's revenue rose 47.2% and profit rose 176.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 22 weeks. This describes what the data did, not a rating. — as of 7 August 2026.
What stage is Lloyds Enterprises Ltd in?
Turning around — profit growth swung from −45.3% at the trough to +176.0% off a 4-quarter-old trough (single-quarter readings), ROCE slipping at 4.0%. The read comes from the last 12 quarters of growth (revenue growth +47.2% latest, profit growth +176.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 7 August 2026.
Is Lloyds Enterprises Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 12 of stage 2), trading +25.4% versus its 200-day average and at the very top of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 7 August 2026.
Is Lloyds Enterprises Ltd beating the market?
On recent form, yes — Lloyds Enterprises Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 22 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +2,155% against the NIFTY 500's +280% — ahead of the index over the full window. — as of 7 August 2026.
Will Lloyds Enterprises Ltd's share price go up?
This page publishes no price forecast for Lloyds Enterprises Ltd. What it measures instead: the share price is ₹83.4, the price is in a confirmed uptrend 12 weeks in. Its P/E of 1,155.0× sits at the 100th percentile of its own 8-year range. — as of 7 August 2026.
Who owns Lloyds Enterprises Ltd?
Promoters hold 62.7% of Lloyds Enterprises Ltd, foreign institutions 0.7%, domestic institutions 0.1% and the public 36.5% (latest quarter). The biggest move on the register over the last two years: Promoters cut 11.2 points over 8 quarters. — as of 7 August 2026.
Does Lloyds Enterprises Ltd have too much debt?
No — Lloyds Enterprises Ltd's debt-to-equity is 0.19, and operating profit covers the interest bill 2×. FY26 borrowings were ₹798 Cr against equity of ₹4,143 Cr. The returns on this page are earned, not borrowed — as of 7 August 2026.
What is Lloyds Enterprises Ltd's capex?
Lloyds Enterprises Ltd spent ₹496 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹222 Cr, with ₹71.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 7 August 2026.
What is Lloyds Enterprises Ltd's cash flow?
Lloyds Enterprises Ltd consumed ₹361 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−583 Cr). Operating cash was negative while the company reported a profit of ₹417 Cr. Cash-flow resolution for India is annual. — as of 7 August 2026.
Is Lloyds Enterprises Ltd's profit real cash?
No — operating cash was negative over the last 3 fiscal years: Lloyds Enterprises Ltd consumed cash while reporting profit. In FY26, operating cash was ₹−361 Cr against reported profit of ₹417 Cr. Cash-flow resolution is annual — as of 7 August 2026.
Where is Lloyds Enterprises Ltd in its business cycle?
Lloyds Enterprises Ltd's FY26 operating margin was 7.0%, against a 13-year band of −311.0%–13.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 6.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 7 August 2026.
What could break the Lloyds Enterprises Ltd story?
The sharpest disagreement: profits are rising, but only −33% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 7 August 2026.
Is Lloyds Enterprises Ltd a stock worth studying right now?
This is not investment advice. The machine read: Lloyds Enterprises Ltd's earnings have outrun its stock. EPS grew +413.5% in a year against a +8.8% price move. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 7 August 2026.